aplb glutathione niacinamide sunscreen Face Soothes and calms irritations APLB Glutathione Niacinamide Sunscreen SPF50+

A striking development in modern obesity pharmacotherapy has been the pairing of Cagrilintide and Semaglutide into a single co-formulation

The M07.6x code is sequenced as an additional code

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes

RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)

You deserve an anti-aging strategy that respects your biology and works with your body, and we partner with you to design a plan aligned with your goals